

**9th Paris Hepatitis Conference  
How to improve access to therapy? Around the  
World Table**

**11 January 2016, Paris, France**

# **National Hepatitis C Elimination Program of Georgia**

**Tengiz Tsertsvadze MD, PhD**

**Director General  
Infectious Diseases, AIDS and Clinical  
Immunology Research Center  
Professor of Medicine, Tbilisi State University**

# HCV Epidemiology in Georgia


Country population: 3.7 million

## HCV in General Population

### 2015 National Survey

	%	# Persons
anti-HCV+	7.1%	193 000
HCV RNA+	5.16%	140 000


## HCV Genotype Distribution



Note: NS5B and 5'UTR/Core sequencing studies indicate that more than half of HCV genotype 2 patients in Georgia are actually infected with 2k/1b recombinant strain


# National Hepatitis C Elimination Program

**Launched in April 2015**



**Gilead Committed to provide Sofosbuvir and  
Ledipasvir/Sofosbuvir free of charge**

**Elimination of HCV infection in the country  
(zero new infections) through identifying and treating  
all hepatitis C patients and through wide-scale  
implementation of prevention interventions**



# National Hepatitis C Elimination Program

## Phase I

2015

Treat 6,000 patients:

- F3/F4 fibrosis
- Severe extrahepatic manifestations
- HIV/HCV co-infection

Available

DAA

- Sofosbuvir

## Phase II

2016-2020


Implementation of large scale combination HCV prevention strategy, including seek, test and treat

Available DAAs

- Sofosbuvir
- Harvoni

Harvoni will be used not only for genotype 1, but for genotype 3 and even for genotype 2, considering high prevalence of recombinant strains in Georgia.

# HCV Care Cascade: December 31, 2015



## Sustained Virologic Response (SVR) Among Patients for Whom Complete Data is Available (n=352)

	SVR Rate			
	G1	G2	G3	TOTAL
IFN-containing regimens	<b>75%</b> (133/178)	<b>94%</b> (45/48)	<b>95%</b> (103/108)	<b>84%</b> (281/334)
IFN-free regimens	-	<b>72%</b> (13/18)	-	<b>72%</b> (13/18)
<b>TOTAL</b>	<b>75%</b> (133/178)	<b>88%</b> (58/66)	<b>95%</b> (103/108)	<b>84%</b> (294/352)

Note: All patients received Sofosbuvir containing regimen

# Targets


# 90-95-95

**By 2020**

- ✓ **90%** of people living with HCV are diagnosed
- ✓ **95%** of those diagnosed are treated
- ✓ **95%** of those treated are cured



# Projected Cascade of HCV Care



# persons:      140 000      126 000      120 400      113 400